

P&T Motion History
Biologic Drugs for Asthma and Urticaria

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
benralizumab dupilumab* mepolizumab omalizumab reslizumab	<p>After considering the evidence of safety, efficacy and special populations for the treatment of asthma and chronic spontaneous urticaria, I move that benralizumab, dupilumab, mepolizumab, omalizumab, and reslizumab are safe and efficacious for the treatment of their approved indications. Benralizumab, dupilumab, mepolizumab, and reslizumab can be subject to therapeutic interchange in the Washington preferred drug list for asthma and chronic spontaneous urticaria.</p> <p>Motion: Park 2nd: Buccola</p>	April 21, 2021	NA	No	Passed unanimous

Bold = new this update

Grey* = Categorized under Atopic Dermatitis on WA PDL

4/6/2021